



Vermillion to Participate at the Piper Jaffray 31st Annual Healthcare Conference

AUSTIN, Texas, November 21, 2019 – Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced that management will participate at the Piper Jaffray 31st Annual Healthcare Conference, taking place December 3-5, 2019 in New York City.

About Vermillion, Inc.

Vermillion, Inc. is transforming women’s health with the discovery, development and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. OVA1[®]plus combines our FDA-cleared products OVA1[®] and OVERA[®] to detect risk of ovarian malignancy in women with adnexal masses. Recently launched, ASPIRA GenetiXSM testing offers both targeted and comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment Vermillion has expertise in cutting-edge research to inform our next generation of products. Our focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection and optimize treatment plans.

Visit our website for more information about our products at www.vermillion.com.

Investor Relations Contact:

Ashley R. Robinson

LifeSci Advisors, LLC

Tel 617-430-7577

Arr@LifeSciAdvisors.com